- Home
- LOGI vs GH Comparison
LOGI vs GH Comparison
Compare LOGI & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOGI | GH |
|---|---|---|
| Founded | 1981 | 2011 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2B | 17.3B |
| IPO Year | 1997 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LOGI | GH |
|---|---|---|
| Price | $107.77 | $131.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 19 |
| Target Price | $106.75 | ★ $119.79 |
| AVG Volume (30 Days) | 1.1M | ★ 2.4M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | ★ 16.22 | 6.74 |
| EPS | ★ 4.80 | N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | $8.30 | $33.30 |
| Revenue Next Year | $2.68 | $28.27 |
| P/E Ratio | $22.06 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $83.32 | $40.36 |
| 52 Week High | $129.66 | $135.00 |
Technical Indicators
Market Signals| Indicator | LOGI | GH |
|---|---|---|
| Relative Strength Index (RSI) | 46.80 | 65.11 |
| Support Level | $106.79 | $122.76 |
| Resistance Level | $112.95 | $134.28 |
| Average True Range (ATR) | 3.28 | 6.05 |
| MACD | -1.55 | -1.11 |
| Stochastic Oscillator | 8.78 | 71.83 |
Price Performance
Historical ComparisonAbout LOGI Logitech International S.A.
Logitech was founded in 1981 and is headquartered in Lausanne, Switzerland. The company specializes in designing and manufacturing computer peripherals such as mice, keyboards, webcams, conference room cameras, headsets, and music-related products like wireless speakers.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.